資源描述：
《肝癌介入治療患者實(shí)施臨床路徑管理的護(hù)理效果.doc》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在工程資料-天天文庫。
1、肝癌介入治療患者實(shí)施臨床路徑管理的護(hù)理效果［摘要］目的探討肝癌介入治療患者實(shí)施臨床路徑管理的臨床護(hù)理效果。方法選取濟(jì)南市第四人民醫(yī)院2007年5月?2010年4月實(shí)施臨床路徑管理前進(jìn)行肝癌介入治療的181例患者為對(duì)照組，2012年5月?2014年4月實(shí)施臨床路徑管理后進(jìn)行肝癌介入治療的194例患者為觀察組，比較兩組患者在生存質(zhì)量、住院時(shí)間、治療費(fèi)用、不良反應(yīng)發(fā)生率以及護(hù)理滿意度等方面的差異。結(jié)果兩組患者在身體功能、心理狀況、社會(huì)功能三個(gè)維度比較，差異有高度統(tǒng)計(jì)學(xué)意義(卩0.05)o觀察組不良反應(yīng)
2、失眠(12.9%).惡心嘔吐(12.9%).肝區(qū)疼痛(10.3%)、尿潴留(5.2%)、穿刺點(diǎn)出血(0.0%)發(fā)生率均低于對(duì)照組(50.3%、44.8%.3&7%、17.7%.11.6%),差異有統(tǒng)計(jì)學(xué)意義(P0.05)o兩組患者滿意度比較，差異有統(tǒng)計(jì)學(xué)意義(P<0.05)o結(jié)論臨床路徑管理有助于提高肝癌介入治療患者生存質(zhì)量及護(hù)理滿意度，減少不良反應(yīng)發(fā)生率，并縮短患者住院時(shí)間及減少住院費(fèi)用，具有一定臨床應(yīng)用價(jià)值。［關(guān)鍵詞］臨床路徑療程；肝癌；介入治療；護(hù)理［中圖分類號(hào)］R735.7［文獻(xiàn)標(biāo)識(shí)碼］
3、A［文章編號(hào)］1673-7210(2015)10(a)-0160-04Nursingeffect,ofclinicalpathwaymanagementforhepatocellularcarcinomapatientswithinterventionaltherapyLIULeilMAOGang2HANLi31.DepartmentofGastroenterology,theFourth卩eople'sHospitalofJinanCity,ShandongProvince,Ji'nan250
4、031,China；2.DepartmentofIntensiveCareUnit,theFourthPeople"sHospitalofJi?nanCity,ShandongProvince,Ji'nan250031,China；3.QualityManagementOffice,theFourthPeople'sHospitalofJi，nanCity,ShandongProvince,Ji，nan250031,China[Abstract]ObjectiveToevaluatethecli
5、nicalnursingeffectofclinicalpathwaymanagementinpatientswithinterventionaltherapy.MethodsTntheFourth卩eople'sHospitalofJi'nanCity,fromMay2007toApril2010,beforeimplementingtheclinicalpathmanagement,181hepatocellularcarcinomapatientswithinterventionalthe
6、rapywereselectedascontrolgroup；fromMay2012toApril2014,afterimplementingtheclinicalpalhwaymanagement,194hepatocellularcarcinomapatientswithinterventionaltherapywereselectedasobservationgroup.Thedifferencesofsurvivetreatment,hospitalstay,treatmentcost,
7、incidenceofadversereactionsandnursingsatisfactionofpatientsbetweentwogroupswerecompared.ResultsThethreedimensionsofphysicalfunction,mentalstatus,socialfunctionintwogroupswerecompared,thedifferenceswerestatisticallysignificant(P0.05)?Theincidenceofadv
8、ersereactions,insomnia(12.9%),nauseaandvomiting(12.9%),liverpain(10.3%),urinaryretention(5.2%)ofobservationgroupwere1owerthanthoseofcontrolgroup(50.3%,44.8%,38.7%,17.7%,11.6%),thedifferenceswerestatisticallysignificant(P0.05)?Thesatisfactionofpatient
